-
Anand Hardikar: a scientific nomad searching for the truth Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-04-23 Susan Rahimi, Marta Koch
-
Endpoints for clinical trials in type 1 diabetes drug development Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-04-23 Alfonso Galderisi, Brynn E Marks, Linda A DiMeglio, Carine de Beaufort
-
Food additive emulsifiers: a new risk factor for type 2 diabetes? Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-04-23 Mengxi Du, Frank B Hu
-
The Human Insulin Thermal Solution project—a private sector initiative to address the thermostability of insulin Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-04-23 Mats Rasmussen, Morten Hach, Jørgen Iwersen, Gayathri Anil, Henrik Rosborg, Jens Larsen, Lise Camilla Hoffmann, Peter Kurtzhals
-
Environmental chemical obesogens, what can we do? Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-04-23 Tim Lobstein
-
Food additive emulsifiers and the risk of type 2 diabetes: analysis of data from the NutriNet-Santé prospective cohort study Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-04-23 Clara Salame PhD, Guillaume Javaux MSc, Laury Sellem PhD, Emilie Viennois PhD, Fabien Szabo de Edelenyi PhD, Cédric Agaësse RD, Alexandre De Sa RD, Inge Huybrechts PhD, Fabrice Pierre PhD, Prof Xavier Coumoul PhD, Prof Chantal Julia PhD, Emmanuelle Kesse-Guyot PhD, Benjamin Allès PhD, Léopold K Fezeu PhD, Prof Serge Hercberg PhD, Mélanie Deschasaux-Tanguy PhD, Prof Emmanuel Cosson MD, Sopio Tatulashvili
Experimental studies have suggested potential detrimental effects of emulsifiers on gut microbiota, inflammation, and metabolic perturbations. We aimed to investigate the associations between exposures to food additive emulsifiers and the risk of type 2 diabetes in a large prospective cohort of French adults. We analysed data from 104 139 adults enrolled in the French NutriNet-Santé prospective cohort
-
Rethinking the label anti-obesity medication Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-04-23 Stuart W Flint
-
Vitamin D supplements and future fracture risk among Mongolian schoolchildren Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-04-23 Ning Ma, Xia Cui, Wenquan Niu
-
Vitamin D supplements and future fracture risk among Mongolian schoolchildren – Author's reply Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-04-23 Adrian R Martineau, Polyna Khudyakov, Davaasambuu Ganmaa
-
Earth Day: time for transformational change Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-04-20 The Lancet Diabetes & Endocrinology
-
Endocrine health in survivors of adult-onset cancer Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-04-08 Cornelia S Link-Rachner MD, Andy Göbel PhD, Nikolai P Jaschke PhD, Tilman D Rachner MD
Long-term survivors of cancer (ie, the patient who is considered cured or for whom the disease is under long-term control and unlikely to recur) are at an increased risk of developing endocrine complications such as hypothalamic–pituitary dysfunctions, hypogonadisms, osteoporosis, or metabolic disorders, particularly when intensive tumour-directed therapies are applied. Symptom severity associated
-
Direct-to-consumer services: improving access to care for people with diabetes and obesity Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-04-05 Talha Burki
-
Glycaemic index as part of the diabetes prevention strategy Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-04-05 Gary Frost
-
Associations of the glycaemic index and the glycaemic load with risk of type 2 diabetes in 127 594 people from 20 countries (PURE): a prospective cohort study Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-04-05 Victoria Miller PhD, Prof David A Jenkins MD PhD, Mahshid Dehghan PhD, Kristie Srichaikul MD, Sumathy Rangarajan MSc, Andrew Mente PhD, Viswanathan Mohan DSc, Prof Sumathi Swaminathan PhD, Prof Rosnah Ismail DrPH, Maria Luz Diaz MD, Rekha M Ravindran PhD, Katarzyna Zatonska MD, Ahmad Bahonar MD, Prof Yuksel Altuntas MD, Rasha Khatib PhD, Prof Patricio Lopez-Jaramillo PhD, Afzalhussein Yusufali MD,
The association between the glycaemic index and the glycaemic load with type 2 diabetes incidence is controversial. We aimed to evaluate this association in an international cohort with diverse glycaemic index and glycaemic load diets. The PURE study is a prospective cohort study of 127 594 adults aged 35–70 years from 20 high-income, middle-income, and low-income countries. Diet was assessed at baseline
-
Type 1 diabetes: heterogeneity in heritability Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-03-29 Richard David Leslie
-
Familial aggregation and heritability of childhood-onset and adult-onset type 1 diabetes: a Swedish register-based cohort study Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-03-29 Yuxia Wei MSc, Shengxin Liu PhD, Tomas Andersson BSc, Prof Maria Feychting PhD, Ralf Kuja-Halkola PhD, Sofia Carlsson PhD
Type 1 diabetes in children is known to be highly heritable, but much less is known about the heritability of adult-onset type 1 diabetes. Thus, our objective was to compare the familial aggregation and heritability of type 1 diabetes in adults and children. This Swedish nationwide register-based cohort study included individuals born from Jan 1, 1982, to Dec 31, 2010, identified through the Medical
-
How clinically relevant is statin-induced diabetes? Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-03-27 Hertzel C Gerstein, Marie Pigeyre
-
Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-03-27 Cholesterol Treatment Trialists’ (CTT) Collaboration, Christina Reith, David Preiss, Lisa Blackwell, Jonathan Emberson, Enti Spata, Kelly Davies, Heather Halls, Charlie Harper, Lisa Holland, Kate Wilson, Alistair J Roddick, Christopher P Cannon, Robert Clarke, Helen M Colhoun, Paul N Durrington, Shinya Goto, Graham A Hitman, G Kees Hovingh, J Wouter Jukema, Wolfgang Koenig, Ian Marschner, Borislava
-
Disparities in fragility fracture and osteoporosis care in Africa Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-03-22 Kate A Ward, Tafadzwa Madanhire, Kebba Marenah, Lisa K Micklesfield, Celia L Gregson
-
Bridging the worlds of research and policy making Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-03-19 Jonathan Valabhji
-
Evaluating the effect of bempedoic acid on kidney function: call for cautious implementation – Authors' reply Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-03-19 Kausik K Ray, LeAnne Bloedon, Na Li, Steven E Nissen, on behalf of the co-authors
-
Evaluating the effect of bempedoic acid on kidney function: call for cautious implementation Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-03-19 Dion Groothof, Stephan J L Bakker
-
Tight versus liberal blood-glucose control in the intensive care unit: special considerations for patients with diabetes Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-03-19 Christian von Loeffelholz MD, Prof Andreas L Birkenfeld MD
Stress hyperglycaemia, hypoglycaemia, and diabetes are common in critically ill patients and related to clinical endpoints. To avoid complications related to hypoglycaemia and hyperglycaemia, it is recommended to start insulin therapy for the majority of critically ill patients with persistent blood glucose concentrations higher than 10·0 mmol/L (>180 mg/dL), targeting a range of 7·8–10·0 mmol/L (140–180
-
Undiagnosed type 2 diabetes: an invisible risk factor Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-03-06 The Lancet Diabetes & Endocrinology
-
-
Long-term trial outcomes of Roux-en-Y gastric bypass and one anastomosis gastric bypass: tipping the scale Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-03-04 Paulina Salminen
-
Optimising zoledronate treatment holiday duration without loss of fracture prevention Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-03-04 Matthew T Drake
-
Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass at 5 years (YOMEGA): a prospective, open-label, non-inferiority, randomised extension study Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-03-04 Prof Maud Robert MD, Tigran Poghosyan MD, Prof Delphine Maucort-Boulch MD, Dr Alexandre Filippello MD, Prof Robert Caiazzo MD, Adrien Sterkers MD, Lita Khamphommala MD, Prof Fabian Reche MD, Vincent Malherbe MD, Adriana Torcivia MD, Toufic Saber MD, Dominique Delaunay PhD, Carole Langlois-Jacques MSc, Augustin Suffisseau MD, Sylvie Bin MD, Prof Emmanuel Disse MD, Prof François Pattou MD
The multicentre randomised trial YOMEGA () comparing the one anastomosis gastric bypass (OAGB) with the Roux-en-Y gastric bypass (RYGB) confirmed the non-inferiority of OAGB on weight loss outcomes at 24 months. We aimed to report weight loss, metabolic, and safety outcomes at 5 years. YOMEGA is a prospective, open-label, non-inferiority, randomised trial conducted at nine centres in France. Inclusion
-
Duration of fracture prevention after zoledronate treatment in women with osteopenia: observational follow-up of a 6-year randomised controlled trial to 10 years Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-03-04 Prof Ian R Reid MD, Anne M Horne MBChB, Borislav Mihov BPhty, Usha Bava MHSc, Angela Stewart RN, Gregory D Gamble MSc
We previously identified that zoledronate administered at 18-month intervals reduced fragility fractures by a third in a 6-year trial of women older than 65 years with osteopenia. This extension aims to identify the persistence of these effects. Of the 2000 ambulant, community dwelling, postmenopausal women older than 65 years recruited in Auckland, New Zealand, with T-scores at the total hip or femoral
-
Reversibility of congenital hypogonadotropic hypogonadism: lessons from a rare disease Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-03-01 Bradley D Anawalt
-
Classes and predictors of reversal in male patients with congenital hypogonadotropic hypogonadism: a cross-sectional study of six international referral centres Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-03-01 Andrew A Dwyer PhD, Isabella R McDonald DNP, Biagio Cangiano MD, Luca Giovanelli MD, Luigi Maione MD, Leticia F G Silveira MD, Prof Taneli Raivio MD PhD, Prof Ana Claudia Latronico MD PhD, Prof Jacques Young MD PhD, Richard Quinton MD, Marco Bonomi MD, Prof Luca Persani MD PhD, Prof Stephanie B Seminara MD, Prof Christopher S Lee PhD
Although some male patients with congenital hypogonadotropic hypogonadism (CHH) undergo spontaneous reversal following treatment, predictors of reversal remain elusive. We aimed to assemble the largest cohort of male patients with CHH reversal to date and identify distinct classes of reversal. This multicentre cross-sectional study was conducted in six international CHH referral centres in Brazil,
-
Type 2 diabetes remission: weight maintenance in the spotlight Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-02-28 Shahrad Taheri
-
CONCEPTT to care: the science of implementation in diabetes care Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-02-26 Eleanor M Scott, Helen R Murphy, Karen Kennedy, Partha Kar
-
5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-02-26 Prof Michael EJ Lean MD, Wilma S Leslie PhD, Alison C Barnes PGDip, Naomi Brosnahan PhD, George Thom PhD, Louise McCombie BSc, Tara Kelly BSc, Keaton Irvine MSci, Carl Peters MB, Sviatlana Zhyzhneuskaya MD, Prof Kieren G Hollingsworth PhD, Prof Ashley J Adamson PhD, Prof Falko F Sniehotta PhD, Prof John C Mathers PhD, Yvonne McIlvenna MSc, Prof Paul Welsh PhD, Prof Alex McConnachie PhD, Alasdair McIntosh
In DiRECT, a randomised controlled effectiveness trial, weight management intervention after 2 years resulted in mean weight loss of 7·6 kg, with 36% of participants in remission of type 2 diabetes. Of 36 in the intervention group who maintained over 10 kg weight loss at 2 years, 29 (81%) were in remission. Continued low-intensity dietary support was then offered up to 5 years from baseline to intervention
-
Living between two worlds: lessons for community involvement Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-02-20 Ashley H Ng, Matthew Quigley, Tim Benson, Lauren Cusack, Rachel Hicks, Ben Nash, Meaghan Read, Renza Scibilia, Cheryl Steele, Leon Tribe, Elizabeth Holmes-Truscott
-
Thank you to The Lancet Diabetes & Endocrinology's statistical and peer reviewers in 2023 Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-02-20
-
Milestone achievement for global access to blood glucose meters and test strips Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-02-20 Emma Klatman, Beatrice Vetter, Cathy Haldane, Graham Ogle
-
Denosumab in the treatment of osteoporosis associated with chronic kidney disease Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-02-16 Adrian Covic, Mugurel Apetrii
-
Women in science: inspiring future generations Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-02-09
-
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-02-05 Carel W le Roux, Oren Steen, Kathryn J Lucas, Elena Startseva, Anna Unseld, Anita M Hennige
-
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-02-05 Yiming Mu, Xiaolei Bao, Freddy G Eliaschewitz, Morten Rix Hansen, Bom Taeck Kim, Anna Koroleva, Ronald C W Ma, Tao Yang, Ning Zu, Ming Liu
-
Glucagon—a new player in weight management therapeutics? Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-02-05 Stephen C Bain, David M Williams
-
GLP-1 analogue therapy for obesity in people from Asia Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-02-05 Bernard Khoo, Tricia M-M Tan
-
A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-01-29 Ken K Y Ho, Maria Fleseriu, John Wass, Laurence Katznelson, Gerald Raverot, Andrew S Little, Justo P Castaño, Martin Reincke, M Beatriz Lopes, Ursula B Kaiser, Philippe Chanson, Mônica Gadelha, Shlomo Melmed
No comprehensive classification system that guides prognosis and therapy of pituitary adenomas exists. The 2022 WHO histopathology-based classification system can only be applied to lesions that are resected, which represent few clinically significant pituitary adenomas. Many factors independent of histopathology provide mechanistic insight into causation and influence prognosis and treatment of pituitary
-
PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-02-02 Michael J Koren, Olivier Descamps, Yoshiki Hata, Ellen Margo Hengeveld, G Kees Hovingh, Ignatios Ikonomidis, Maria D Radu Juul Jensen, Irene Hedelund Langbakke, Fabrice M A C Martens, Anette Luther Søndergaard, Adam Witkowski, Wolfgang Koenig
Background Currently available injectable drugs that target proprotein convertase subtilisin/kexin type 9 (PCSK9) reduce serum LDL cholesterol and improve cardiovascular outcomes. This phase 2 study assessed NNC0385-0434, an oral PCSK9 inhibitor, in individuals receiving oral lipid-lowering therapy. Methods In this randomised, double-blind, placebo-controlled and active-controlled trial, 42 research
-
An anti-PCSK9 pill a day to keep cholesterol away: next steps? Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-02-02 Gerald F Watts
Abstract not available
-
Air pollution exposure and cardiometabolic risk Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-02-02 Sanjay Rajagopalan, Robert D Brook, Pedro R V O Salerno, Brendan Bourges-Sevenier, Philip Landrigan, Mark J Nieuwenhuijsen, Thomas Munzel, Salil V Deo, Sadeer Al-Kindi
The Global Burden of Disease assessment estimates that 20% of global type 2 diabetes cases are related to chronic exposure to particulate matter (PM) with a diameter of 2·5 μm or less (PM2·5). With 99% of the global population residing in areas where air pollution levels are above current WHO air quality guidelines, and increasing concern in regard to the common drivers of air pollution and climate
-
Correction to Lancet Diabetes Endocrinol 2024; 12: 39–50 Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-01-29
Abstract not available
-
TB Joshua and his megachurch: fake medical miracles and abuse in Nigeria Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-01-29 Talha Burki
Abstract not available
-
The impact of the COVID-19 pandemic and associated disruptions in health-care provision on clinical outcomes in people with diabetes: a systematic review Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-01-23 Jamie Hartmann-Boyce, Patrick Highton, Karen Rees, Igho Onakpoya, Jana Suklan, Ffion Curtis, Lauren O'Mahoney, Elizabeth Morris, Laura Kudlek, Jessica Morgan, Rosie Lynch, Sanjana Marpadga, Samuel Seidu, Kamlesh Khunti
The COVID-19 pandemic triggered disruptions to health care and lifestyles that could conceivably impact diabetes management. We set out to identify the impact of disruptions caused by COVID-19 on clinical outcomes in people with diabetes. We performed a systematic review of the available literature in the MEDLINE and OVID databases from Jan 1, 2020, to June 7, 2023, and included 138 studies (n>1 000 000
-
The price of health Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-01-23
Abstract not available
-
Association of glycaemic index and glycaemic load with type 2 diabetes and related conditions in prospective studies Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-01-23 Gabriele Riccardi, Olga Vaccaro
Abstract not available
-
Anti-obesity drugs, eating disorders, and thinness among Japanese young women Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-01-23 Shotaro Kinoshita, Taishiro Kishimoto
Abstract not available
-
Rafik Jacob: Caring for the most vulnerable Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-01-23 Talha Burki
Abstract not available
-
Correction to Lancet Diabetes Endocrinol 2023; 11: 42–57 Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-01-23
Abstract not available
-
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality: a meta-analysis of mega cohorts of more than 100 000 participants Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-01-23 David J A Jenkins, Walter C Willett, Salim Yusuf, Frank B Hu, Andrea J Glenn, Simin Liu, Andrew Mente, Victoria Miller, Shrikant I Bangdiwala, Hertzel C Gerstein, Sabina Sieri, Pietro Ferrari, Alpa V Patel, Marjorie L McCullough, Loïc Le Marchand, Neal D Freedman, Erikka Loftfield, Rashmi Sinha, Xiao-Ou Shu, Mathilde Touvier, Wanning Yang
Background There is debate over whether the glycaemic index of foods relates to chronic disease. We aimed to assess the associations between glycaemic index (GI) and glycaemic load (GL) and type 2 diabetes, cardiovascular disease, diabetes-related cancers, and all-cause mortality. Methods We did a meta-analysis of large cohorts (≥100 000 participants) identified from the Richard Doll Consortium. We
-
The fight to put food on the table: from past to present | Pen Vogler, Stuffed: A History of Good Food and Hard Times in Britain, Atlantic Books (2023), p. 453, £22·00, ISBN: 9781838955748 Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-01-05 Talha Burki
Abstract not available
-
Better testing and labelling of drugs for people with obesity Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-01-04 Talha Burki
Abstract not available
-
The role of medical students in humanitarian responses to armed conflict Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-01-03 Ji Won Susie Yoo, Rahul D Barmanray
Abstract not available
-
Bringing an end to diabetes stigma and discrimination: an international consensus statement on evidence and recommendations Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-12-19 Jane Speight, Elizabeth Holmes-Truscott, Matthew Garza, Renza Scibilia, Sabina Wagner, Asuka Kato, Victor Pedrero, Sonya Deschênes, Susan J Guzman, Kevin L Joiner, Shengxin Liu, Ingrid Willaing, Katie M Babbott, Bryan Cleal, Jane K Dickinson, Jennifer A Halliday, Eimear C Morrissey, Giesje Nefs, Shane O'Donnell, Anna Serlachius, Timothy C Skinner
People with diabetes often encounter stigma (ie, negative social judgments, stereotypes, prejudice), which can adversely affect emotional, mental, and physical health; self-care, access to optimal health care; and social and professional opportunities. To accelerate an end to diabetes stigma and discrimination, an international multidisciplinary expert panel (n=51 members, from 18 countries) conducted